CVS Health's Earnings Power Inflection: GLP-1 Strategy, Aetna Flowback, and a Credible 2027 Floor
A decisive Q2 beat-and-raise, $2B cash flow guidance boost, and a pulled-forward 2027 EPS floor of $8.44 signal a durable turnaround with fresh growth levers.
CVS · Earnings Call · 2026-08-05
Strong Quarter, Broad-Based Growth
CVS Health delivered a decisive second-quarter beat, with all three segments growing earnings and adjusted EPS of $2.58 (up >40% y/y). Management raised full-year 2026 EPS guidance by $0.60 to $7.90–$8.10 and lifted cash flow from operations guidance by $2B to at least $11.5B. As CEO David Joyner stated, “We are raising our full year 2026 adjusted earnings per share guidance by $0.60 to a range of $7.90 to $8.10.” — J. Joyner · 2026-08-05 He also underscored the cash flow strength: “We are updating our full year expectation for cash flow from operations to at least $11.5 billion, a meaningful increase of $2 billion from our prior guidance.” — Brian Newman · 2026-08-05 This is a clear inflection from the impairment-laden 2024 and sets the stage for a confident forward outlook. Operating income surged 39% y/y to $4.7B in Q1 2026, leading a steady recovery in margins. The strength is not just a one-off. Excluding the impact of individual exchange risk adjustment and prior-year development, core performance still exceeded expectations, particularly in Medicare where medical cost management and disciplined pricing are paying off. The Medical Benefit Ratio improved to 87.4% in Q2, a strong signal for the legacy Aetna turnaround.GLP-1 and Health100: New Growth Levers
CVS is pivoting from a passive pharmacy role to an active consumer health-technology platform. The GLP-1s for weight loss push is a prime example: the company is leveraging MinuteClinic's virtual weight management offering (now $29/visit), manufacturer partnerships with Lilly and Novo, and its omnichannel pharmacy to capture both funded and cash-pay demand. This is a company-unique theme, not just sector boilerplate. As Prem Shah highlighted, “We continued to create innovative solutions like Cordavis, where we launched a biosimilar, and that's generated over $1.8 billion of savings on just Humira for our customers.” — Prem Shah · 2026-08-05 The GLP-1 initiative is further differentiated by the Health100 platform, which integrates AI-powered consumer engagement—a strategic shift toward being a "consumer-based health care technology company," as David noted earlier in the year. This is a fresh, forward-looking theme that could drive both cost savings and new revenue streams across the enterprise.Aetna Flowback, 340B Headwind, and 2027 Floor
The Aetna turnaround is accelerating, with more than $2B of year-over-year adjusted operating income improvement delivered in the first half of 2026. Management remains committed to returning to target margins by 2028, and the recently pulled-forward 2027 guidance provides a tangible floor. CFO Brian Newman said,This is a rare early look at next year and reflects confidence in the earnings power despite acknowledged headwinds. In the 340B business, pressure from manufacturer restrictions and the selling season dynamics in Caremark are real, but management is positioning selling season discipline as a deliberate, underwriting-focused move. The specialty pharmacy tailwind remains a durable offset, and the company reiterates its mid-teens EPS CAGR through 2028. Prior calls laid the groundwork for this confidence. In Q1 2026, David noted the inflection: “We see this really as an inflection point in our business.” — J. Joyner, Chair and Chief Executive Officer · 2026-05-06 And back in Q4 2025, he anchored the Aetna commitment: “We are committed to the Aetna margins, and that commitment remains unchanged.” — J. Joyner, Chair and Chief Executive Officer · 2026-02-10 Both are playing out in the numbers. Combined with the use of AI across claims processing, provider experiences, and pharmacy operations—delivering over $1B in OpEx savings—CVS is demonstrating that the turnaround is not just a one-time beat but a sustainable operational improvement. The stock's 17% rally over the past 90 days is a market acknowledgment, even as the valuation remains reasonable (price-to-revenue of 0.2x). With a credible 2027 floor and clear catalysts, CVS Health is back on the front foot.I think a reasonable floor, Mike, for '27 for adjusted EPS should be – could be $8.44, and that's obviously consistent with current consensus.